Get the Stockscreener App
1.09
9.17%
-0.11
After Hours:
1.09
Enlivex Ltd stock is traded at $1.09, with a volume of 777.63K.
It is down -9.17% in the last 24 hours and down -5.22% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$1.20
Open:
$1.17
24h Volume:
777.63K
Relative Volume:
1.43
Market Cap:
$259.67M
Revenue:
-
Net Income/Loss:
$-12.70M
P/E Ratio:
-2.0404
EPS:
-0.5342
Net Cash Flow:
$-12.36M
1W Performance:
+0.93%
1M Performance:
-5.22%
6M Performance:
+5.83%
1Y Performance:
+3.81%
1-Day Range:
$1.08
$1.17
1-Week Range:
$1.015
$1.32
52-Week Range:
$0.66
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
1.09 | 285.88M | 0 | -12.70M | -12.36M | -0.5342 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 - marketscreener.com
Published on: 2026-03-26 22:45:56 - baoquankhu1.vn
Enlivex Reports Full-Year 2025 Results, Profit of $1.23 Billion and Diluted Earnings per Share of $25.48 - marketscreener.com
Enlivex Highlights Rain’s AI Agent Launch and $5 Million Grant Program to Expand Prediction Markets - TipRanks
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt - The Manila Times
Enlivex (NASDAQ: ENLV) highlights Rain AI launch, $5M grants and RAIN token burn - Stock Titan
One prompt can now create a live prediction market as Rain adds $5M - Stock Titan
Enlivex Obtains $21 Million Loan to Purchase RAIN Tokens and Initiate $20 Million Buyback - Bitget
Enlivex shares jump after earnings as treasury gains boost results - MSN
Earnings call transcript: Enlivex Q4 2025 sees stock surge on treasury gains - Investing.com Australia
Envilex Therapeutics (ENLV) Reports Strong FY GAAP EPS - GuruFocus
Enlivex Soars After FDA Approval for Allocetra Trial - StocksToTrade
Enlivex Stock Boosted by FDA Approval for Allocetra in Osteoarthritis Trials - timothysykes.com
Enlivex Allocetra Takes A Leap as FDA Clears Phase 2b Trial for Osteoarthritis - timothysykes.com
Enlivex Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 - Bitget
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS - MarketBeat
Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation - Quiver Quantitative
Biotech–crypto hybrid Enlivex (NASDAQ: ENLV) outlines RAIN treasury risks and funding needs - Stock Titan
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted ... - Bluefield Daily Telegraph
Enlivex (NASDAQ: ENLV) nets $1.23B in 2025 on digital treasury gains - Stock Titan
Treasury gains push Enlivex to $1.23B profit, $2.31B in assets - Stock Titan
Enlivex secures $21M debt financing, buys more RAIN tokens By Investing.com - Investing.com Australia
Strategic Move: Enlivex Allocates $21 Million for RAIN Token Acquisition Amid Share Buyback - MEXC
Enlivex Raises $21 Million to Expand RAIN Token Treasury Holdings - Blockonomi
Enlivex Raises $21M to Expand RAIN Token Treasury and Biotechnology Pipeline - MoneyCheck
Enlivex Secures $21M Funding to Boost RAIN Treasury Strategy - CoinCentral
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex stock rating held at Hold by D. Boral Capital after debt deal - Investing.com Australia
Enlivex Funding Rounds, Token Sale Review & Tokenomics Analysis - CryptoRank
Enlivex secures $21M debt financing, buys more RAIN tokens - Investing.com
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback - TipRanks
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program - The Manila Times
Enlivex (Nasdaq: ENLV) adds $21M financing and $20M share repurchase plan - Stock Titan
Backed by $21M debt, Enlivex buys 3B more RAIN tokens at discount - Stock Titan
FDA clears Enlivex knee osteoarthritis therapy for phase 2b trial By Investing.com - Investing.com Australia
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis - Stocktwits
Enlivex (ENLV) Gains FDA Approval for Osteoarthritis Drug Trial - GuruFocus
Enlivex Therapeutics announces FDA clearance of Allocetra new drug application - TipRanks
Enlivex Gets Investigational New Drug Clearance in US for Phase 2b Trial of Knee Osteoarthritis Treatment - marketscreener.com
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis - TipRanks
FDA clears Enlivex (Nasdaq: ENLV) Phase 2b Allocetra trial in knee osteoarthritis - Stock Titan
FDA clears Enlivex study for knee arthritis drug in older adults - Stock Titan
Enlivex Therapeutics Tokenized Stock (Ondo) price today, ENLVon to USD live price, marketcap and chart - CoinMarketCap
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday - Defense World
CEO Change: How does Enlivex Therapeutics Ltd score in quality rankings2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aug Rallies: Can Enlivex Therapeutics Ltd sustain earnings growthPrice Action & Community Verified Watchlist Alerts - baoquankhu1.vn
AI Stocks: Is Enlivex Therapeutics Ltd in a long term uptrend2026 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | 1BT | IL0011319527 - marketscreener.com
ENLV (NASDAQ: ENLV) trims ATM program to $250M, prior sales noted - Stock Titan
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):